vs

Side-by-side financial comparison of Ambiq Micro, Inc. (AMBQ) and IRIDEX CORP (IRIX). Click either name above to swap in a different company.

Ambiq Micro, Inc. is the larger business by last-quarter revenue ($18.2M vs $14.7M, roughly 1.2× IRIDEX CORP).

Ambiq Micro, Inc. is an American semiconductor company specializing in low-power microcontrollers and systems-on-chip, including products for devices smartwatches, medical devices, and sensors. Founded in 2010 by University of Michigan researchers Scott Hanson, David Blaauw, and Dennis Sylvester, the company is headquartered in Austin, Texas. Its products employ Subthreshold Power Optimized Technology (SPOT) to reduce energy consumption and enable on-device edge AI. In 2025, Ambiq went public...

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

AMBQ vs IRIX — Head-to-Head

Bigger by revenue
AMBQ
AMBQ
1.2× larger
AMBQ
$18.2M
$14.7M
IRIX

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
AMBQ
AMBQ
IRIX
IRIX
Revenue
$18.2M
$14.7M
Net Profit
$-9.0M
Gross Margin
42.3%
37.2%
Operating Margin
-55.3%
Net Margin
-49.6%
Revenue YoY
-69.7%
Net Profit YoY
EPS (diluted)
$-0.72

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMBQ
AMBQ
IRIX
IRIX
Q4 25
$14.7M
Q3 25
$18.2M
$12.5M
Q2 25
$17.9M
$13.6M
Q1 25
$11.9M
Q4 24
$12.7M
Q3 24
$11.6M
Q2 24
$12.6M
Q1 24
$11.8M
Net Profit
AMBQ
AMBQ
IRIX
IRIX
Q4 25
Q3 25
$-9.0M
$-1.6M
Q2 25
$-8.5M
$-994.0K
Q1 25
$-1.7M
Q4 24
$-834.0K
Q3 24
$-1.9M
Q2 24
$-2.7M
Q1 24
$-3.5M
Gross Margin
AMBQ
AMBQ
IRIX
IRIX
Q4 25
37.2%
Q3 25
42.3%
32.1%
Q2 25
40.1%
34.5%
Q1 25
42.5%
Q4 24
44.0%
Q3 24
37.3%
Q2 24
40.7%
Q1 24
37.9%
Operating Margin
AMBQ
AMBQ
IRIX
IRIX
Q4 25
Q3 25
-55.3%
-11.3%
Q2 25
-49.2%
-6.9%
Q1 25
-1.7%
Q4 24
-3.9%
Q3 24
-16.1%
Q2 24
-20.9%
Q1 24
-28.0%
Net Margin
AMBQ
AMBQ
IRIX
IRIX
Q4 25
Q3 25
-49.6%
-12.6%
Q2 25
-47.5%
-7.3%
Q1 25
-14.2%
Q4 24
-6.6%
Q3 24
-16.7%
Q2 24
-21.2%
Q1 24
-29.5%
EPS (diluted)
AMBQ
AMBQ
IRIX
IRIX
Q4 25
Q3 25
$-0.72
$-0.09
Q2 25
$-18.89
$-0.06
Q1 25
$-0.10
Q4 24
$-0.05
Q3 24
$-0.12
Q2 24
$-0.16
Q1 24
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMBQ
AMBQ
IRIX
IRIX
Cash + ST InvestmentsLiquidity on hand
$146.5M
$6.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$169.8M
Total Assets
$186.7M
$29.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMBQ
AMBQ
IRIX
IRIX
Q4 25
$6.0M
Q3 25
$146.5M
$5.6M
Q2 25
$47.5M
$6.8M
Q1 25
$7.2M
Q4 24
$2.4M
Q3 24
$3.9M
Q2 24
$4.1M
Q1 24
$5.4M
Total Debt
AMBQ
AMBQ
IRIX
IRIX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.0M
Q3 24
$1.4M
Q2 24
Q1 24
Stockholders' Equity
AMBQ
AMBQ
IRIX
IRIX
Q4 25
Q3 25
$169.8M
$4.7M
Q2 25
$-307.3M
$6.1M
Q1 25
$852.0K
Q4 24
$2.1M
Q3 24
$2.6M
Q2 24
$4.2M
Q1 24
$6.5M
Total Assets
AMBQ
AMBQ
IRIX
IRIX
Q4 25
$29.2M
Q3 25
$186.7M
$28.4M
Q2 25
$89.2M
$31.6M
Q1 25
$34.2M
Q4 24
$29.1M
Q3 24
$30.2M
Q2 24
$31.2M
Q1 24
$34.1M
Debt / Equity
AMBQ
AMBQ
IRIX
IRIX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.48×
Q3 24
0.53×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMBQ
AMBQ
IRIX
IRIX
Operating Cash FlowLast quarter
$-5.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMBQ
AMBQ
IRIX
IRIX
Q4 25
Q3 25
$-5.0M
$-1.2M
Q2 25
$-10.5M
$-397.0K
Q1 25
$-1.1M
Q4 24
$-1.2M
Q3 24
$-3.1M
Q2 24
$-1.3M
Q1 24
$-1.6M
Free Cash Flow
AMBQ
AMBQ
IRIX
IRIX
Q4 25
Q3 25
$-1.2M
Q2 25
$-410.0K
Q1 25
$-1.2M
Q4 24
$-1.2M
Q3 24
$-3.1M
Q2 24
Q1 24
$-1.7M
FCF Margin
AMBQ
AMBQ
IRIX
IRIX
Q4 25
Q3 25
-9.4%
Q2 25
-3.0%
Q1 25
-9.8%
Q4 24
-9.8%
Q3 24
-26.5%
Q2 24
Q1 24
-14.0%
Capex Intensity
AMBQ
AMBQ
IRIX
IRIX
Q4 25
Q3 25
0.1%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMBQ
AMBQ

Customer Concentration Risk$16.2M89%
Other$2.0M11%

IRIX
IRIX

Segment breakdown not available.

Related Comparisons